# Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC)

> **NCT03285321** · PHASE2 · COMPLETED · sponsor: **Greg Durm, MD** · enrollment: 105 (actual)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Nivolumab
- **DRUG:** Nivolumab
- **DRUG:** Ipilimumab

## Key facts

- **NCT ID:** NCT03285321
- **Lead sponsor:** Greg Durm, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-09-15
- **Primary completion:** 2023-10-13
- **Final completion:** 2024-02-06
- **Target enrollment:** 105 (ACTUAL)
- **Last updated:** 2026-01-20

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03285321

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03285321, "Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03285321. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*